

HepG2 experiments original blots

Apigenin and luteolin induce autophagy by targeting NRH-quinone oxidoreductase 2 in liver cells

Elzbieta Janda^{1, 2*}, Concetta Martino¹, Concetta Riillo^{1, 2}, Maddalena Parafati¹, Antonella Lascalea¹, Vincenzo Mollace^{1, 2}, Jean A. Boutin³

1 Department of Health Sciences, Magna Graecia University, Campus Germaneto, Catanzaro, Italy;

2 Interregional Research Center for Food Safety and Health, Catanzaro, Italy


3 PHARMADEV (Pharmacochimie et biologie pour le développement), Université Toulouse 3 Paul Sabatier, Faculté de Pharmacie, Toulouse, France

* Correspondence: janda@unicz.it;

This supplementary document shows all original Western blots (WB) presented in Fig. 3-6 of the manuscript. The chemiluminescence signal was acquired with Chemidoc camera and converted in tiff images by Quantity One software. All blots are annotated with antigen targeted by immunoblotting and exposure time used to acquire the signal. In case of multiple signals due to sequential blots or non-specific bands, the last blotted antigen is indicated with arrows. Some blots are shown with two alternative exposure times, but more exposure times are available for all blots.

Fig. 3A (left panels)

HepG2 siNQO2 +/-Api/Lut +/-ClQ Exp02A E1304SZ



HepG2 siNQO2 +Api/Lut +ClQ Exp01B E1304SZ



Fig. 4A
(upper panel)

HepG2 +K3 +/-CIQ_12%_1st_ GEL2




Fig. 4A
(lower panel)




Fig. 4B
(upper panel)

HepG2 +Adrenoch +/-CIQ_12%




Fig. 4B
(lower panel)









Fig. 4C
(upper panel)**Fig. 4C**
(lower panel)

Fig. 5A

HepG2 +Lut 10/30 or +Api10/30 (6h) SDS-PAGE 10% GEL1
E2302SZ

upper panel



second panel








Fig. 5B

HepG2 siPRKB +/-Api/Lut E2604SZL 2704
SDS-PAGE 8%


Janda et al. 2021 Supplementary file




WB: anti-phAMPK (Th172) Fig. 5B, 1° upper panel



WB: anti-AMPKα Fig. 5B, 2nd upper panel




WB: TUBA Fig. 5B, 3rd panel




WB: anti-PRKAB Fig. 5B, 4th panel

Fig. 5B


HepG2 siPRKB +/-Api/Lut, E2604SZL 2704
SDS-PAGE 12% , GEL A




HepG2 siPRKB +/-Api/Lut +CIQ E2604SZL 2704
SDS-PAGE 12% , GEL B, +CIQ



WB: anti-LC3 and anti-NQO2, Fig. 5B, 7th panel




WB: anti-LC3 and anti-NQO2, Fig. 5B, 8th panel




WB: anti-GAPDH (arrow) and anti-NQO2, Fig. 5B, last panel

Fig. 6 SDS-PAGE 12%




WB: anti-NQO2 (arrow) and anti-GAPDH(*),
Fig. 6, upper panel 1

SDS-PAGE 8%




WB: anti-phAMPK Fig. 6, panel 2

SDS-PAGE 8%



WB: anti-AMPK Fig. 6, panel 3



WB: anti-TUBA Fig. 6, panel 4